- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01807299
The Effect of Physical Training and the Omega 3 Consumption on Attention Deficit Hyperactivity Disorder in Children (AOE)
February 17, 2020 updated by: Jose Carlos Fernandes Galduroz MD, Federal University of São Paulo
The Effect of Physical Training and the Omega 3 Consumption on Attention Deficit
The attention deficit hyperactivity disorder (ADHD) usually occurs in preschool and may cause disabilities through whole life.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The attention deficit hyperactivity disorder (ADHD) usually occurs in preschool and may cause disabilities through whole life.
The treatment of this disease is expensive and difficult.
Moreover, physical exercise and omegas consumption may improve the cognitive functions and behavior, so it could be an interesting strategy to improve this disorder.
The aim of the present study is to verify the effects of multiple components physical training and the consumption of omega 3 on behavior, cognitive functions and the serum levels of BDNF and IGF-1 in ADHD children.
Thus, 68 ADHD children, between seven and fourteen years old will be selected.
The volunteers will be randomly divided into four groups: Physical Training Group (PTG), Omega Group (OG), Omega and Physical Training Group (OPTG) and Control Group (CG).
The protocol of the experiment will last three months in which the OPTG will make physical training and receive fish oil capsules, and the PTG will make only the physical training and receive a placebo of fish oil.
The others groups will be oriented not to make any type of physical training, but the OG will receive fish oil capsule, and the CG will receive a placebo of fish oil.
Behavioral and cognitive functions evaluations and blood analysis will be made at the beginning and at the end of the protocol.
Study Type
Interventional
Enrollment (Actual)
68
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
São Paulo, Brazil, 04024002
- Departamento de Psicobiologia
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
7 years to 14 years (Child)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Children with ADHD: male, between seven and fourteen years old, sedentary, studing in a regular school.
Exclusion Criteria:
- Taking psychoactive medications, taking omega supplement.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Physical Training
The training group will make physical exercise for three months (three times a week).
|
Capsules of omega 3, 1000mg / capsules.
Administered 3 times a day.
|
Other: Sedentary
The sedentary group will be oriented not to make any type of physical training for three months.
|
Capsules of omega 3, 1000mg / capsules.
Administered 3 times a day.
|
Placebo Comparator: Placebo
The omega 3 group will receive 2g per day of mineral oil during 90 days treatment
|
|
Experimental: Omega 3
The omega 3 group will receive 2g per day of fish oil during 90 days treatment
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Conners Scale
Time Frame: 3 months
|
Scores on the Conners scale.
Scores above 60 indicate ADHD.
Minimum 0 and a maximum of 126.
|
3 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: José Carlos F Galduróz, Md PhD, Universidade Federal de São Paulo (UNIFESP)
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2011
Primary Completion (Actual)
March 1, 2013
Study Completion (Actual)
May 1, 2015
Study Registration Dates
First Submitted
March 7, 2013
First Submitted That Met QC Criteria
March 7, 2013
First Posted (Estimate)
March 8, 2013
Study Record Updates
Last Update Posted (Actual)
February 28, 2020
Last Update Submitted That Met QC Criteria
February 17, 2020
Last Verified
February 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ADHD_Omega_Exercise
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Attention Deficit Hyperactivity Disorder
-
Cingulate TherapeuticsRecruitingPhase 3 Efficacy and Safety Laboratory Classroom Study in Pediatrics (6-12) With ADHD Using CTx-1301ADHD | Attention Deficit Hyperactivity Disorder | Attention Deficit Disorder With Hyperactivity | ADHD - Combined Type | Attention Deficit Hyperactivity Disorder Combined | Attention Deficit Hyper Activity | Attention-deficit HyperactivityUnited States
-
Ornit CohenUnknownAttention Deficit Hyperactivity Disorder | Attention Deficit Disorder With Hyperactivity | Attention Deficit Disorder | Attention Deficit Disorders With Hyperactivity | Attention Deficit Hyperactivity DisordersIsrael
-
Cingulate TherapeuticsPremier Research Group plcActive, not recruitingADHD | Attention Deficit Hyperactivity Disorder | ADHD - Combined Type | Attention Deficit Hyperactivity Disorder Combined | Attention Deficit Hyper Activity | Attention-deficit HyperactivityUnited States
-
Children's National Research InstituteRecruitingADHD | Attention Deficit Hyperactivity Disorder | Attention-Deficit Hyperactivity Disorder | Attention Deficit Disorder | ADD | ADHD Predominantly Inattentive Type | ADHD - Combined Type | ADHD, Predominantly Hyperactive - Impulsive | Attention-Deficit Disorder in Adolescence | Attention-Deficit Hyperactivity...United States
-
Fondation LenvalCompletedAttention Deficit Disorder With Hyperactivity | Attention Deficit Disorder Without HyperactivityFrance
-
University Hospital Bispebjerg and FrederiksbergMental Health Services in the Capital Region, DenmarkRecruitingSleep Disturbance | Neurodevelopmental Disorders | Attention Deficit Hyperactivity Disorder | Attention Deficit Disorder | Attention-Deficit Hyperactivity Disorder, Unspecified Type | Attention-deficit Hyperactivity | Hyperkinetic Conduct DisorderDenmark
-
Corium, Inc.Worldwide Clinical Trials; Premier Research Group plc; Almac; Prometrika, LLCRecruitingAttention Deficit/Hyperactivity DisorderUnited States
-
Corium, Inc.Premier Research Group plc; Almac; Prometrika, LLCRecruitingAttention Deficit/Hyperactivity DisorderUnited States
-
Massachusetts General HospitalShire Human Genetic Therapies, Inc.Active, not recruitingAttention Deficit/Hyperactivity DisorderUnited States
-
Ataturk UniversityCompletedAttention-deficit/Hyperactivity DisorderTurkey
Clinical Trials on Omega 3
-
Ohio State University Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletedBreast Neoplasms | ArthralgiaUnited States
-
Pennington Biomedical Research CenterCompleted
-
AstraZenecaCompletedDiabetes Mellitus, Type 2 | Exocrine Pancreatic InsufficiencySweden, Poland, Latvia, Denmark, Hungary, Slovakia
-
Appalachian State UniversityCompleted
-
Seoul National University HospitalUnknown
-
Université de SherbrookeNot yet recruiting
-
Collegium Medicum w BydgoszczyUnknownChronic Kidney Disease | Cardiovascular ComplicationsPoland
-
Haukeland University HospitalUniversity of Oslo; University of BergenCompletedCardiovascular Disease
-
Université de SherbrookeSamuel Fortin, SFC pharma and associate professor UQARCompleted
-
Mayo ClinicNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National... and other collaboratorsCompleted